Steven N Goodman

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4249951/steven-n-goodman-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16,545 128 123 53 h-index g-index citations papers 6.93 148 19,910 10.7 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
123	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021 , 21, 117	70 ⁴	11
122	Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1185-1195	27.4	110
121	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021 , 12, 2349	17.4	83
120	Randomized COVID-19 vaccination rollout can offer direct real-world evidence. <i>Journal of Clinical Epidemiology</i> , 2021 , 138, 199-202	5.7	3
119	Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. <i>JAMA Network Open</i> , 2021 , 4, e2111417	10.4	109
118	The Role of Masks in Mitigating the SARS-CoV-2 Pandemic: Another Piece of the Puzzle. <i>Annals of Internal Medicine</i> , 2021 , 174, 419-420	8	5
117	U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013-2018. <i>Annals of Internal Medicine</i> , 2021 , 174, 1603-1611	8	4
116	Preprint Servers Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1901-1903	27.4	12
115	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020 , 9, 1193	3.6	28
114	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020 , 9, 1193	3.6	22
113	How often do leading biomedical journals use statistical experts to evaluate statistical methods? The results of a survey. <i>PLoS ONE</i> , 2020 , 15, e0239598	3.7	12
112	Calibrating the Scientific Ecosystem Through Meta-Research. <i>Annual Review of Statistics and Its Application</i> , 2020 , 7, 11-37	7.6	23
111	Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults. <i>JAMA Neurology</i> , 2020 , 77, 1241-1251	17.2	20
110	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. <i>Annals of Internal Medicine</i> , 2020 , 172, 35-45	8	79
109	How often do leading biomedical journals use statistical experts to evaluate statistical methods? The results of a survey 2020 , 15, e0239598		
108	How often do leading biomedical journals use statistical experts to evaluate statistical methods? The results of a survey 2020 , 15, e0239598		
107	How often do leading biomedical journals use statistical experts to evaluate statistical methods? The results of a survey 2020 , 15, e0239598		

(2017-2020)

How often do leading biomedical journals use statistical experts to evaluate statistical methods? 106 The results of a survey **2020**, 15, e0239598 Why is Getting Rid of P-Values So Hard? Musings on Science and Statistics. American Statistician, 105 22 2019, 73, 26-30 Urodynamic factors associated with the large capacity bladder and incomplete emptying after 104 2.3 1 prolapse repair (2009-2015). Neurourology and Urodynamics, 2019, 38, 1322-1331 Harms From Uninformative Clinical Trials. JAMA - Journal of the American Medical Association, 2019, 36 103 27.4 322, 813-814 Random-Effects Assumption in Meta-analyses-Reply. JAMA - Journal of the American Medical 102 27.4 Association, 2019, 322, 82 Should Psychology Journals Adopt Specialized Statistical Review?. Advances in Methods and 6 101 13.3 Practices in Psychological Science, 2019, 2, 240-249 The high resource impact of reformatting requirements for scientific papers. PLoS ONE, 2019, 14, e02239.76 100 7 Lost Evidence From Registered Large Long-Unpublished Randomized Controlled Trials: A Survey. 99 10 Annals of Internal Medicine, 2019, 171, 300-301 Random-Effects Meta-analysis: Summarizing Evidence With Caveats. JAMA - Journal of the American 98 27.4 64 Medical Association, 2019, 321, 301-302 Lack of Diagnostic Utility of "Amino Acid Dysregulation Metabotypes". Biological Psychiatry, 2019, 97 7.9 85, e41-e42 Redefine statistical significance. Nature Human Behaviour, 2018, 2, 6-10 1168 96 12.8 How and why studies disagree about the effects of education on health: A systematic review and 95 5.1 55 meta-analysis of studies of compulsory schooling laws. Social Science and Medicine, 2018, 212, 168-178 Assessing scientists for hiring, promotion, and tenure. PLoS Biology, 2018, 16, e2004089 94 9.7 133 2007 The clinical research operations program: Educating clinical research staff. Journal of Clinical 0.4 78 93 and Translational Science, 2018, 2, 61-61 Annals Understanding Clinical Research: Interpreting Results With Large P Values. Annals of Internal 8 92 5 Medicine, 2018, 169, 485-486 Five ways to fix statistics. *Nature*, **2017**, 551, 557-559 62 91 50.4 Sharing Clinical Research Data-Finding the Right Balance. JAMA Internal Medicine, 2017, 177, 1241-1242 11.5 1 90 Posing Causal Questions When Analyzing Observational Data-Reply. JAMA - Journal of the American 89 27.4 Medical Association, **2017**, 318, 201-202

88	Using big data analytics to extract disease surveillance information from point of care diagnostic machines. <i>Pervasive and Mobile Computing</i> , 2017 , 42, 470-486	3.5	17
87	What does research reproducibility mean?. <i>Science Translational Medicine</i> , 2016 , 8, 341ps12	17.5	506
86	Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. <i>Clinical Trials</i> , 2016 , 13, 621-631	2.2	20
85	STATISTICS. Aligning statistical and scientific reasoning. <i>Science</i> , 2016 , 352, 1180-1	33.3	61
84	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. <i>European Journal of Epidemiology</i> , 2016 , 31, 337-50	12.1	1122
83	Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 30-8	12.9	121
82	Clinical trial data sharing: what do we do now?. Annals of Internal Medicine, 2015, 162, 308-9	8	6
81	Meta-research: Evaluation and Improvement of Research Methods and Practices. <i>PLoS Biology</i> , 2015 , 13, e1002264	9.7	127
80	Data monitoring committees for pragmatic clinical trials. Clinical Trials, 2015, 12, 530-6	2.2	20
79	Random-effects meta-analysis of inconsistent effects: a time for change. <i>Annals of Internal Medicine</i> , 2014 , 160, 267-70	8	273
78	P Value 2014 ,		1
77	Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. <i>Biostatistics</i> , 2014 , 15, 23-7; discussion 39-45	3.7	9
76	Causal inference in public health. Annual Review of Public Health, 2013, 34, 61-75	20.6	173
75	The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. <i>Hastings Center Report</i> , 2013 , Spec No, S4-S15	3.3	165
74	An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. <i>Hastings Center Report</i> , 2013 , Spec No, S16-27	3.3	314
73	Raw data from clinical trials: within reach?. <i>Trends in Pharmacological Sciences</i> , 2013 , 34, 645-7	13.2	36
7 ²	Advances in regulatory science at the Food and Drug Administration. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 2103-4	27.4	9
71	The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. <i>PLoS ONE</i> , 2013 , 8, e68966	3.7	23

(2009-2013)

70	All that glitters isnR gold: a survey on acknowledgment of limitations in biomedical studies. <i>PLoS ONE</i> , 2013 , 8, e73623	3.7	8
69	The methods of comparative effectiveness research. Annual Review of Public Health, 2012, 33, 425-45	20.6	103
68	Ethical considerations in studying drug safetythe Institute of Medicine report. <i>New England Journal of Medicine</i> , 2012 , 367, 959-64	59.2	19
67	Quasi-random reflections on randomized controlled trials and comparative effectiveness research. <i>Clinical Trials</i> , 2012 , 9, 22-6	2.2	6
66	An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. <i>Clinical Cancer Research</i> , 2011 , 17, 4494-503	12.9	107
65	Analysis of subgroup effects in randomized trials when subgroup membership is missing: application to the second Multicenter Automatic Defibrillator Intervention Trial. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2011 , 60, 607-617	1.5	2
64	Diastolic blood pressure levels and ischemic stroke incidence in older adults with white matter lesions. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2011 , 66, 74-81	6.4	10
63	Landmark clinical trials: a new journal series. <i>Clinical Trials</i> , 2011 , 8, 128	2.2	
62	Confessions of a chagrined trialist. <i>BMJ Quality and Safety</i> , 2011 , 20 Suppl 1, i97-8	5.4	4
61	Harry Marks: an appreciation. <i>Clinical Trials</i> , 2011 , 8, 123-7	2.2	О
60	Harry Marks: an appreciation. <i>Clinical Trials</i> , 2011 , 8, 123-7 Commentary. <i>Biostatistics</i> , 2010 , 11, 389-90	2.2 3·7	O 2
			2
60	Commentary. <i>Biostatistics</i> , 2010 , 11, 389-90 Bias and trials stopped early for benefit. <i>JAMA - Journal of the American Medical Association</i> , 2010 ,	3·7 27·4	2
60 59	Commentary. <i>Biostatistics</i> , 2010 , 11, 389-90 Bias and trials stopped early for benefit. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 157; author reply 158-9	3·7 27·4	13
60 59 58	Commentary. <i>Biostatistics</i> , 2010 , 11, 389-90 Bias and trials stopped early for benefit. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 157; author reply 158-9 High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010 , 115, 2136-4 High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host	3·7 27·4 112.2	2 13 91
60 59 58 57	Commentary. <i>Biostatistics</i> , 2010 , 11, 389-90 Bias and trials stopped early for benefit. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 157; author reply 158-9 High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010 , 115, 2136-4 High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i> , 2010 , 115, 3224-30	3·7 27·4 112.2	2 13 91 281
60 59 58 57 56	Commentary. <i>Biostatistics</i> , 2010 , 11, 389-90 Bias and trials stopped early for benefit. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 157; author reply 158-9 High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010 , 115, 2136-4 High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i> , 2010 , 115, 3224-30 Building a Bayesian bridge from evidence to guidelines. <i>Archives of Internal Medicine</i> , 2009 , 169, 1436-7	3·7 27·4 112.2 2.2	2 13 91 281 5

52	Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 242-	·8 ^{4·7}	52
51	Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. <i>Annals of Internal Medicine</i> , 2009 , 151, 206-9	8	230
50	An intervention to improve cancer patientsRunderstanding of early-phase clinical trials. <i>IRB: Ethics & Human Research</i> , 2009 , 31, 1-10		32
49	Circulating mutant DNA to assess tumor dynamics. <i>Nature Medicine</i> , 2008 , 14, 985-90	50.5	1718
48	Systematic reviews are not biased by results from trials stopped early for benefit. <i>Journal of Clinical Epidemiology</i> , 2008 , 61, 95-6; author reply 96-8	5.7	12
47	A dirty dozen: twelve p-value misconceptions. <i>Seminars in Hematology</i> , 2008 , 45, 135-40	4	319
46	Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. <i>Journal of Urology</i> , 2008 , 179, 743-7	2.5	44
45	RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. <i>Cancer Research</i> , 2008 , 68, 7975-84	10.1	286
44	Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear?. Journal of Empirical Research on Human Research Ethics, 2008, 3, 57-68	1.6	46
43	P Value 2008 , 1		
42	Reproducible research: moving toward research the public can really trust. <i>Annals of Internal Medicine</i> , 2007 , 146, 450-3	8	119
41	Stopping at nothing? Some dilemmas of data monitoring in clinical trials. <i>Annals of Internal Medicine</i> , 2007 , 146, 882-7	8	43
40	Disclosure of individual surgeon® performance rates during informed consent: ethical and epistemological considerations. <i>Annals of Surgery</i> , 2007 , 245, 507-13	7.8	23
39	Why most published research findings are false: problems in the analysis. <i>PLoS Medicine</i> , 2007 , 4, e168	11.6	53
38	Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 996-1004	9.7	210
37	Ethical issues in evidence-based surgery. <i>Surgical Clinics of North America</i> , 2006 , 86, 151-68, x	4	17
36	The methodologic ozone effect. <i>Epidemiology</i> , 2005 , 16, 430-5	3.1	8
35	Introduction to Bayesian methods I: measuring the strength of evidence. <i>Clinical Trials</i> , 2005 , 2, 282-90; discussion 301-4, 364-78	2.2	103

(1999-2005)

34	A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barr yndrome. <i>Clinical Trials</i> , 2005 , 2, 305-10; discussion 364-78	2.2	35
33	Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 84°	1 3-7 9	8
32	Detection and quantification of mutations in the plasma of patients with colorectal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 16368-73	11.5	858
31	Role and limitations of epidemiology in establishing a causal association. <i>Seminars in Cancer Biology</i> , 2004 , 14, 413-26	12.7	22
30	Catalytic asymmetric total syntheses of quinine and quinidine. <i>Journal of the American Chemical Society</i> , 2004 , 126, 706-7	16.4	149
29	Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimerß disease: a systematic review. <i>Neuroepidemiology</i> , 2004 , 23, 159-69	5.4	318
28	Toward protecting the safety of participants in clinical trials. Contemporary Clinical Trials, 2003, 24, 256	-71	51
27	Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 1634-7	9.7	94
26	Commentary: The P-value, devalued. International Journal of Epidemiology, 2003, 32, 699-702	7.8	17
25	The Mammography Dilemma. <i>Annals of Internal Medicine</i> , 2003 , 138, 771	8	1
24	Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. <i>Clinical Cancer Research</i> , 2003 , 9, 1370-5	12.9	105
23	Enantiopure beta-hydroxy morpholine amides from terminal epoxides by carbonylation at 1 atm. <i>Angewandte Chemie - International Edition</i> , 2002 , 41, 4703-5	16.4	53
23		16.4 27.4	53 79
	Angewandte Chemie - International Edition, 2002 , 41, 4703-5 How statistical expertise is used in medical research. <i>JAMA - Journal of the American Medical</i>	27.4	
22	Angewandte Chemie - International Edition, 2002, 41, 4703-5 How statistical expertise is used in medical research. JAMA - Journal of the American Medical Association, 2002, 287, 2817-20	27.4	79
22	Angewandte Chemie - International Edition, 2002, 41, 4703-5 How statistical expertise is used in medical research. JAMA - Journal of the American Medical Association, 2002, 287, 2817-20 Acne therapy: a methodologic review. Journal of the American Academy of Dermatology, 2002, 47, 231-4 Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and	27.4 4 0 4.5	79
22 21 20	Angewandte Chemie - International Edition, 2002, 41, 4703-5 How statistical expertise is used in medical research. JAMA - Journal of the American Medical Association, 2002, 287, 2817-20 Acne therapy: a methodologic review. Journal of the American Academy of Dermatology, 2002, 47, 231-4 Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. Journal of General Internal Medicine, 2000, 15, 56-67 Bayesian communication: a clinically significant paradigm for electronic publication. Journal of the	27.4 40 _{4.5}	79 119 96

16	Toward evidence-based medical statistics. 2: The Bayes factor. <i>Annals of Internal Medicine</i> , 1999 , 130, 1005-13	8	562
15	Probability at the bedside: the knowing of chances or the chances of knowing?. <i>Annals of Internal Medicine</i> , 1999 , 130, 604-6	8	34
14	Bayesian analysis for a single 2 x 2 table. <i>Statistics in Medicine</i> , 1998 , 17, 2147-8	2.3	
13	Statistical reviewing policies of medical journals: caveat lector?. <i>Journal of General Internal Medicine</i> , 1998 , 13, 753-6	4	71
12	What Patients Say about Medical Research. IRB: Ethics & Human Research, 1998, 20, 1		59
11	What patients say about medical research. IRB: Ethics & Human Research, 1998, 20, 1-7		23
10	Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. <i>Human Pathology</i> , 1996 , 27, 119-24	3.7	170
9	Some practical improvements in the continual reassessment method for phase I studies. <i>Statistics in Medicine</i> , 1995 , 14, 1149-61	2.3	384
8	Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. <i>Annals of Surgery</i> , 1995 , 221, 721-31; discussion 731-3	7.8	724
7	Future prospects discussed. <i>Nature</i> , 1994 , 368, 106-107	50.4	6
6	The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. <i>Annals of Internal Medicine</i> , 1994 , 121, 200-6	8	419
5	Manuscript quality before and after peer review and editing at Annals of Internal Medicine. <i>Annals of Internal Medicine</i> , 1994 , 121, 11-21	8	168
4	p values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate. <i>American Journal of Epidemiology</i> , 1993 , 137, 485-96; discussion 497-501	3.8	231
3	A comment on replication, p-values and evidence. <i>Statistics in Medicine</i> , 1992 , 11, 875-9	2.3	203
2	One-sided or two-sided p values?. <i>Contemporary Clinical Trials</i> , 1988 , 9, 387-8		4
1	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials		7